Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jun;19(6):353-361.
doi: 10.1200/OP.23.00016.

Implementing a PROACTive Care Pathway to Empower and Support Survivors of Breast Cancer

Affiliations

Implementing a PROACTive Care Pathway to Empower and Support Survivors of Breast Cancer

Maria Alice Franzoi et al. JCO Oncol Pract. 2023 Jun.

Abstract

Purpose: Optimal comprehensive survivorship care is insufficiently delivered. To increase patient empowerment and maximize the uptake of multidisciplinary supportive care strategies to serve all survivorship needs, we implemented a proactive survivorship care pathway for patients with early breast cancer at the end of primary treatment phase.

Methods: Pathway components included (1) a personalized survivorship care plan (SCP), (2) face-to-face survivorship education seminars and personalized consultation for supportive care referrals (Transition Day), (3) a mobile app delivering personalized education and self-management advice, and (4) decision aids for physicians focused on supportive care needs. A mixed-methods process evaluation was performed according to the Reach, Effectiveness, Adoption, Implementation and Maintenance framework including administrative data review, pathway experience survey (patient, physician, and organization), and focus group. The primary objective was patient-perceived satisfaction with the pathway (predefined progression criteria for pathway continuation ≥70%).

Results: Over 6 months, 321 patients were eligible for the pathway and received a SCP and 98 (30%) attended the Transition Day. Among 126 patients surveyed, 77 (66.1%) responded. 70.1% received the SCP, 51.9% attended the Transition Day, and 59.7% accessed the mobile app. 96.1% of patients were very or completely satisfied with the overall pathway, whereas perceived usefulness was 64.8% for the SCP, 90% for the Transition Day, and 65.2% for the mobile app. Pathway implementation seemed to be positively experienced by physicians and the organization.

Conclusion: Patients were satisfied with a proactive survivorship care pathway, and the majority reported that its components were useful in supporting their needs. This study can inform the implementation of survivorship care pathways in other centers.

PubMed Disclaimer

Conflict of interest statement

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/op/authors/author-center.

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).

Maria Alice Franzoi

Research Funding: Resilience Care (Inst)

Marion Aupomerol

Honoraria: Lilly

Expert Testimony: Novartis

Travel, Accommodations, Expenses: Menarini

Davide Soldato

Honoraria: AstraZeneca

Travel, Accommodations, Expenses: Novartis

Antonio Di Meglio

Expert Testimony: Kephren, techspert.io

Léonor Fasse

Employment: GlaxoSmithKline

Consulting or Advisory Role: Pierre Fabre

Research Funding: GlaxoSmithKline, Amgen Foundation (Inst)

Céline Lazorthes

Employment: Resilience Care

Leadership: Resilience Care

Stock and Other Ownership Interests: Resilience Care

Mario di Palma

Honoraria: AstraZeneca, Novartis

Consulting or Advisory Role: Sandoz

Speakers' Bureau: Amgen, Kyowa Kirin International, MSD Oncology, Mundipharma, Sandoz, Roche

Research Funding: Bayer, Sandoz (Inst), Pierre Fabre (Inst), Fresenius Kabi, Astellas Pharma (Inst), Janssen Oncology (Inst), Roche (Inst), Sanofi (Inst)

Travel, Accommodations, Expenses: Pfizer, Novartis

Suzette Delaloge

Consulting or Advisory Role: AstraZeneca (Inst), Sanofi (Inst), Besins Healthcare (Inst), Rappta Therapeutics (Inst), Gilead Sciences (Inst)

Research Funding: AstraZeneca (Inst), Pfizer (Inst), Roche/Genentech (Inst), Puma Biotechnology (Inst), Lilly (Inst), Novartis (Inst), Sanofi (Inst), Exact Sciences (Inst), Bristol Myers Squibb (Inst), Taiho Pharmaceutical (Inst)

Travel, Accommodations, Expenses: Pfizer, AstraZeneca, Novartis (Inst)

Barbara Pistilli

Consulting or Advisory Role: Puma Biotechnology, Pierre Fabre, Novartis, Myriad Genetics, AstraZeneca, Daiichi Sankyo/UCB Japan

Research Funding: Pfizer (Inst), Puma Biotechnology (Inst), Merus (Inst), Daiichi-Sankyo (Inst), Gilead Sciences (Inst), AstraZeneca (Inst)

Travel, Accommodations, Expenses: Pfizer, AstraZeneca, MSD Oncology, Novartis, Pierre Fabre, Daiichi Sankyo Europe GmbH

Florian Scotté

Honoraria: Leo Phar, Viatris, Pharmanovia, Amgen, Gilead Sciences, BMS GmbH & Co. KG, GlaxoSmithKline

Ines Vaz-Luis

Honoraria: AstraZeneca (Inst), Amgen (Inst), Pfizer (Inst), Novartis (Inst), Sandoz

Research Funding: Resilience Care (Inst)

No other potential conflicts of interest were reported.

Figures

FIG 1.
FIG 1.
Pathway components (personalized SCP, the Transition Day, mobile app, and decision aids for physicians focused on supportive care needs). Digital navigation on the mobile application is offered during The Transition Day. For detailed information in each one of the components refer to the Supplementary Material (Data Supplement, Pages 3-7). PRO-CTCAE, patient-reported outcome Common Terminology Criteria for Adverse Events; Q&A, question and answer; SCP, survivorship care plan.
FIG A1.
FIG A1.
Implementation barriers and strategies to overcome.

Similar articles

Cited by

References

    1. Shapiro CL: Cancer survivorship. N Engl J Med 379:2438-2450, 2018 - PubMed
    1. Siegel RL, Miller KD, Fuchs HE, et al. : Cancer statistics, 2022. CA Cancer J Clin 72:7-33, 2022 - PubMed
    1. Ferreira AR, Di Meglio A, Pistilli B, et al. : Differential impact of endocrine therapy and chemotherapy on quality of life of breast cancer survivors: A prospective patient-reported outcomes analysis. Ann Oncol 30:1784-1795, 2019 - PubMed
    1. Dumas A, Vaz Luis I, Bovagnet T, et al. : Impact of breast cancer treatment on employment: Results of a multicenter prospective cohort study (CANTO). J Clin Oncol 38:734-743, 2020 - PMC - PubMed
    1. Charles C, Bardet A, Larive A, et al. : Characterization of depressive symptoms trajectories after breast cancer diagnosis in women in France. JAMA Netw Open 5:e225118, 2022 - PMC - PubMed

Publication types